NCT07014488已完成1 期
A Single-center, Single-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Area Under the Curve from time 0 to time t (AUC0-t)
研究概览
简要总结
The study was designed to evaluate the pharmacokinetic effects of Rifampicin on HRS-5041 after oral administration of HRS-5041 tablets in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Males aged 18-55 years (inclusive).
- •Male participants whose partner was a woman of childbearing potential were required to use contraception from the time they provided written informed consent until 3 months after the last dose of the investigational product.
- •Weight ≥ 50 kg and body mass index (BMI) : 19-28 kg/m2 (inclusive).
- •Participants were able to communicate well with the investigators, understand and comply with the requirements of the study, and sign the informed consent form.
排除标准
- •Patients who have had or are currently suffering from any clinically serious diseases of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry or metabolic system or any other diseases that may interfere with the test results.
- •Patients who had undergone surgery within 6 months before screening or who were scheduled to undergo surgery during the study or who had undergone any previous surgery affecting gastrointestinal absorption (including gastrectomy, bowel resection, or gastric contraction).
- •Patients who had donated blood or had massive blood loss (≥400 mL), received blood transfusion, or used blood products within 3 months before screening.
- •Allergic constitution, including severe drug allergy or history of drug allergy; He had a history of allergy to HRS-5041 tablets, rifampicin, or their excipients.
- •History of drug abuse within 1 year before screening; Those with positive urine drug abuse screening.
- •Who participated in any clinical trial and took a study drug within 3 months before the first dose.
- •Drinking more than 14 units of alcohol per week in the 6 months prior to screening (1 unit = 285 mL for beer, 25 mL for spirits, or 100 mL for wine); Or have taken alcohol-containing products 48 hours before administration; Or positive alcohol breath test at baseline.
- •Patients with abnormal vital signs and judged by the investigator to be clinically significant.
- •HCV (hepatitis C virus) antibody positive, HIV antibody positive, HBsAg positive, syphilis antibody positive.
- •Those who have special requirements for diet and cannot abide by the uniform diet.
- •Patients with a history of needle fainting and blood fainting, difficulty in blood collection or inability to tolerate venous puncture blood collection.
研究组 & 干预措施
HRS-5041 + Rifampicin
Experimental
干预措施: HRS-5041 Tablets (Drug)
HRS-5041 + Rifampicin
Experimental
干预措施: Rifampicin Capsule (Drug)
结局指标
主要结局
Area Under the Curve from time 0 to time t (AUC0-t)
时间窗: 0 to anticipated 23 days.
Area Under the Curve from time 0 to infinity (AUC0-∞)
时间窗: 0 to anticipated 23 days.
Maximum concentration (Cmax)
时间窗: 0 to anticipated 23 days.
次要结局
- Time to reach maximum concentration (Tmax)(0 to anticipated 23 days.)
- Half-life (t1/2)(0 to anticipated 23 days.)
- Apparent clearance (CL/F)(0 to anticipated 23 days.)
- Adverse events (AEs)(0 to anticipated 31 days.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on FluzoparibHealthy Male SubjectsNCT04011124Jiangsu HengRui Medicine Co., Ltd.16
已完成
1 期
A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on FamitinibHealthy Adult SubjectsNCT04494659Jiangsu HengRui Medicine Co., Ltd.21
已完成
1 期
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy SubjectsAdvanced Solid TumorNCT06198556Jiangsu HengRui Medicine Co., Ltd.18
已完成
1 期
Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy SubjectsHealthy SubjectsNCT04439578Jiangsu HengRui Medicine Co., Ltd.18
已完成
1 期
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected ParticipantsHIV-1-infectionTuberculosisNCT04424264Professor Francois Venter18